China vaccine maker Changsheng plunges again after police launch probe

Reuters  |  SHANGHAI 

By Jourdan

China's drug regulator has accused of fabricating production and inspection records related to a regularly given to infants, sparking public outrage.

While there have been no known reports of people being harmed by the vaccine, Chinese regulators ordered to halt production and recall the product.

Changsheng apologised in a regulatory filing on Monday. The firm was also found to have sold 252,600 substandard DPT vaccines, a mandatory in to inoculate children against diphtheria, and

Changsheng is now being investigated by multiple authorities in China, including the securities regulator and the country's top graft watchdog. The (CCDI) said on Tuesday it had begun an investigation into possible corruption at the firm.

The scandal, which dragged down across the board on Monday, has now wiped around $1.8 billion from Changsheng's Shenzhen-listed shares since mid-July, over half their value.

Chinese citizens have been quick to express their with one discussion hashtag on the microblog gathering over 600 million views. The state-run newspaper said in an editorial late on Monday the case had created a "tsunami" on the internet.

The scandal has prompted speculation that mainland Chinese would take their children outside mainland for vaccines as has happened during previous scandals, which could lead to a shortage in Chinese-controlled regions like Hong Kong or

The Hong Kong told local supply of the vaccines remained stable and it would closely monitor the situation. Macau's health bureau said current supply was sufficient for residents and there was no need for concern.

($1 = 6.8204 Chinese yuan)

(Reporting by Jourdan; Additional reporting by Farah Master and Anne Marie Roantree in HONG KONG; Editing by Edwina Gibbs)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, July 24 2018. 09:43 IST